3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
6
Neoplasms
5
Pain
4
Vomiting
3
Sleep Initiation and Maintenance Disorders
3
Prostatic Neoplasms
3
Nausea
3
Colorectal Neoplasms
3
Polycystic Ovary Syndrome
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Head and Neck Neoplasms
2
Depression
2
Carcinoma, Non-Small-Cell Lung
2
Cancer Pain
2
Anxiety Disorders
2
Acupuncture
2
Xerostomia
1
Urinary Incontinence, Stress
1
Urinary Incontinence
1
Testicular Neoplasms
1
Teratoma
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Radiation Injuries
1
Prostatic Hyperplasia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Nausea and Vomiting
1
Interventions
Bupivacaine
11
Ketamine
9
Ropivacaine
8
Morphine
8
Acetaminophen
8
Fentanyl
7
Dexmedetomidine
7
Lidocaine
6
Anesthesia, General
6
Analgesics, Opioid
6
Saline Solution
5
Anesthesia, Local
5
Acupuncture Therapy
5
parecoxib
4
Tramadol
4
Sodium Chloride
4
Pregabalin
4
Ethanol
4
Analgesia, Epidural
4
Transcutaneous Electric Nerve Stimulation
3
Radiofrequency Ablation
3
Propofol
3
Oxycodone
3
Ketorolac
3
Control Groups
3
Anesthetics, Local
3
trimebutine 3-thiocarbamoylbenzenesulfonate
2
Therapeutics
2
Surveys and Questionnaires
2
Magnesium Sulfate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Agnosia
×
Electroacupuncture
×
Clear all
NCT04917796
2026-01-30
ACT
Dana-Farber Cancer Institute
Phase NA
Active not recruiting
255 enrolled